Compare HCC & XGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HCC | XGN |
|---|---|---|
| Founded | 2015 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Coal Mining | Medical Specialities |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 74.6M |
| IPO Year | 2017 | 2014 |
| Metric | HCC | XGN |
|---|---|---|
| Price | $99.16 | $2.68 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 7 |
| Target Price | ★ $94.71 | $9.14 |
| AVG Volume (30 Days) | ★ 775.6K | 288.5K |
| Earning Date | 04-29-2026 | 03-10-2026 |
| Dividend Yield | ★ 0.33% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $1,310,043,000.00 | N/A |
| Revenue This Year | $59.80 | $8.06 |
| Revenue Next Year | $8.40 | $12.93 |
| P/E Ratio | $88.66 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $38.00 | $2.65 |
| 52 Week High | $105.35 | $12.23 |
| Indicator | HCC | XGN |
|---|---|---|
| Relative Strength Index (RSI) | 66.27 | 30.03 |
| Support Level | $84.15 | N/A |
| Resistance Level | $105.35 | $3.89 |
| Average True Range (ATR) | 4.20 | 0.23 |
| MACD | 1.75 | -0.00 |
| Stochastic Oscillator | 93.71 | 3.46 |
Warrior Met Coal Inc produces and exports met or steelmaking coal, which is used as a component for steel production by metal manufacturers in Europe, South America, and Asia. The company is involved in longwall mining operations in its underground mines based in Alabama, Mine No. 4, Mine No. 7, and Blue Creek. Additionally, its natural gas operations remove and sell natural gas from owned and leased coal seams by reducing natural gas levels in its mines. The company generates revenue mainly through the production of steelmaking coal for sale to the steel industry. Geographically, the firm generates maximum revenue from its customers in Asia, followed by Europe, South America, and the United States.
Exagen Inc is a commercial-stage diagnostics company committed to addressing the unmet need for the accurate diagnosis and monitoring of patients affected by autoimmune rheumatic diseases. It currently markets ten testing products under its Avise brand to provide an accurate, timely, and differential diagnosis and to optimize the treatment of ARDs. It markets and sells solutions to community rheumatologists.